Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Colorcon
Johnson and Johnson
McKinsey
QuintilesIMS
Daiichi Sankyo
McKesson
Merck
Accenture

Generated: April 20, 2018

DrugPatentWatch Database Preview

ABLAVAR Drug Profile

« Back to Dashboard

When do Ablavar patents expire, and when can generic versions of Ablavar launch?

Ablavar is a drug marketed by Lantheus Medcl and is included in one NDA. There is one patent protecting this drug.

This drug has forty-three patent family members in twenty-six countries.

The generic ingredient in ABLAVAR is gadofosveset trisodium. Additional details are available on the gadofosveset trisodium profile page.
Summary for ABLAVAR
International Patents:43
US Patents:1
Applicants:1
NDAs:1
Clinical Trials: 8
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ABLAVAR at DailyMed
Drug patent expirations by year for ABLAVAR

US Patents and Regulatory Information for ABLAVAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 DISCN No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-002 Dec 22, 2008 DISCN No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for ABLAVAR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 ➤ Sign Up ➤ Sign Up
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 ➤ Sign Up ➤ Sign Up
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 ➤ Sign Up ➤ Sign Up
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for ABLAVAR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,229,606 Diagnostic imaging contrast agents with extended blood retention ➤ Sign Up
8,017,105 Diagnostic imaging contrast agents with extended blood retention ➤ Sign Up
8,394,356 Diagnostic imaging contrast agents with extended blood retention ➤ Sign Up
7,011,815 Diagnostic imaging contrast agents with extended blood retention ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for ABLAVAR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB07/011 United Kingdom ➤ Sign Up PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003
0253 Netherlands ➤ Sign Up 300253, 20160116, EXPIRES: 20201002
2007 00016 Denmark ➤ Sign Up
C 037/2006 Ireland ➤ Sign Up SPC 037/2006: 20070528, EXPIRES: 20201002
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Fuji
Daiichi Sankyo
AstraZeneca
McKesson
Deloitte
Chubb
Cerilliant
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.